https://www.thebodypro.com/category/adverse-events-comorbidities-hiv/tag/liver

The Latest

discover opportunities

This Week in HIV Research: The Challenges of Our Assumptions

May 28, 2020: Anal lesion recurrence among women with HIV; non-alcoholic fatty liver disease frequency in lean patients; long-term efficacy for a smoking cessation intervention; non-lymphoid cancers following lymphoid malignancy.

By Barbara Jungwirth and Myles Helfand
data

This Week in HIV Research: There’s No Such Thing as Too Much Data

May 7, 2020: Epidemiological factors among transgender women; revised PrEP indication estimates for MSM; trends in HIV strain similarity between younger and older MSM; current hepatitis C epidemic among British MSM with HIV.

By Barbara Jungwirth and Myles Helfand
David Kalinoski

Creating Care Plans for People Who Use Drugs Or With Hepatitis C in the Time of Coronavirus

VOCAL-NY has kept its doors open through the COVID-19 pandemic to serve people who use drugs and may be living with hepatitis C, but how it provides services has changed.

By Terri Wilder, M.S.W.
virology

This Week in HIV Research: Is Viral Suppression an STI Prevention Tool?

March 5, 2020: How U=U reduces more than HIV transmission; "other" HPV strain risks post-vaccination; vitamin E for nonalcoholic steatohepatitis; HCV therapy and increased cardiovascular risk.

By Barbara Jungwirth and Myles Helfand
Prescription medicine bottles on lipid blood test report

This Week in HIV Research: Much Ado About Lipids

Oct. 17, 2019: Tesamorelin as treatment for non-alcoholic fatty liver disease; reversing lipid changes via TDF => TAF => TDF; statin use and reduced chronic kidney disease risk; statin use and (no) reduced HIV persistence.

By Barbara Jungwirth and Myles Helfand
Various Road Closed signs

Test-and-Treat for Hepatitis C: What Are the Obstacles?

A series of studies aim to determine whether test-and-treat strategies can be implemented for people with hepatitis C, much like programs for people living with HIV.

By Sony Salzman
close up of man's arm getting blood drawn

We Have a Cure for Hepatitis C. Why Are Rates So High?

An in-depth update on what we know about HCV risk, symptoms, screening, outcomes, and treatment (including financial barriers).

By Martha Kempner
Steven Deeks, M.D.

The State of Cure Research for HIV and Hepatitis B: Similarities and Differences

Steven Deeks, M.D., talks about the medical community's hopes, inspirations, and unanswered questions regarding research for an HIV cure.

By Terri Wilder, M.S.W.
pharmacist looking at list

Hepatitis C (HCV) Initial Treatment Recommendations: A Closer Look at the Options

Although several HCV drugs can cure almost all infections regardless of viral genotype, picking the right drug will depend on each patient's medical history, level of liver damage, and coinfections.

By Sony Salzman
couple on the boardwalk surrounded by seagulls

This Week in HIV Research: When STIs Flock Together

July 18, 2019: Anal neoplasia risk amidst comorbid HPV and chlamydia; predictive modeling for PrEP outreach; long-term benefits of hepatitis C cure in coinfection; first-line therapy with dolutegravir/lamivudine.

By Barbara Jungwirth and Myles Helfand